TrickleStar Limited (SGX:CYW)
Singapore · Delayed Price · Currency is SGD 0.0280
+0.0010 (3.70%)
At close: Jul 31, 2025
SpringWorks Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| 11.48 | 10.29 | 13.82 | 11.29 | 12.85 | Upgrade | |
Revenue Growth (YoY) | 11.53% | -25.54% | 22.43% | -12.16% | -11.53% | Upgrade |
Cost of Revenue | 9.06 | 7.9 | 10.32 | 9.49 | 9.65 | Upgrade |
Gross Profit | 2.41 | 2.39 | 3.5 | 1.8 | 3.2 | Upgrade |
Selling, General & Admin | 2.78 | 2.65 | 3.12 | 2.58 | 2.6 | Upgrade |
Other Operating Expenses | 0.27 | 0 | - | - | - | Upgrade |
Operating Expenses | 3.05 | 2.65 | 3.12 | 2.58 | 2.6 | Upgrade |
Operating Income | -0.63 | -0.26 | 0.38 | -0.78 | 0.6 | Upgrade |
Interest Expense | -0.01 | -0.01 | -0.04 | -0.01 | -0 | Upgrade |
Interest & Investment Income | 0 | 0.01 | 0 | 0 | 0 | Upgrade |
Currency Exchange Gain (Loss) | - | 0.02 | 0 | 0.01 | 0.07 | Upgrade |
Other Non Operating Income (Expenses) | 0 | 0 | 0 | 0.07 | 0 | Upgrade |
EBT Excluding Unusual Items | -0.64 | -0.24 | 0.35 | -0.71 | 0.67 | Upgrade |
Asset Writedown | -0.02 | -0 | -0.51 | -1.5 | - | Upgrade |
Legal Settlements | - | - | - | 0.35 | - | Upgrade |
Other Unusual Items | - | - | - | 0.13 | - | Upgrade |
Pretax Income | -0.65 | -0.24 | -0.16 | -1.72 | 0.67 | Upgrade |
Income Tax Expense | 0.01 | 0.03 | -0.6 | 0.52 | -0.04 | Upgrade |
Earnings From Continuing Operations | -0.67 | -0.28 | 0.44 | -2.24 | 0.71 | Upgrade |
Earnings From Discontinued Operations | - | -0.01 | -0.28 | -0.15 | - | Upgrade |
Net Income | -0.67 | -0.28 | 0.16 | -2.39 | 0.71 | Upgrade |
Net Income to Common | -0.67 | -0.28 | 0.16 | -2.39 | 0.71 | Upgrade |
Net Income Growth | - | - | - | - | 306.11% | Upgrade |
Shares Outstanding (Basic) | 84 | 83 | 83 | 82 | 82 | Upgrade |
Shares Outstanding (Diluted) | 84 | 84 | 83 | 82 | 82 | Upgrade |
Shares Change (YoY) | 0.63% | 0.59% | 0.66% | 0.53% | 9.62% | Upgrade |
EPS (Basic) | -0.01 | -0.00 | 0.00 | -0.03 | 0.01 | Upgrade |
EPS (Diluted) | -0.01 | -0.00 | 0.00 | -0.03 | 0.01 | Upgrade |
EPS Growth | - | - | - | - | 270.56% | Upgrade |
Free Cash Flow | -1.93 | 0.68 | 0.36 | 0.51 | 1.68 | Upgrade |
Free Cash Flow Per Share | -0.02 | 0.01 | 0.00 | 0.01 | 0.02 | Upgrade |
Dividend Per Share | - | - | - | 0.002 | 0.004 | Upgrade |
Dividend Growth | - | - | - | -66.67% | - | Upgrade |
Gross Margin | 21.04% | 23.27% | 25.34% | 15.91% | 24.93% | Upgrade |
Operating Margin | -5.52% | -2.49% | 2.73% | -6.92% | 4.69% | Upgrade |
Profit Margin | -5.80% | -2.74% | 1.19% | -21.21% | 5.55% | Upgrade |
Free Cash Flow Margin | -16.78% | 6.57% | 2.61% | 4.50% | 13.10% | Upgrade |
EBITDA | -0.56 | -0.18 | 0.46 | -0.69 | 0.69 | Upgrade |
EBITDA Margin | -4.92% | -1.76% | 3.35% | -6.10% | 5.41% | Upgrade |
D&A For EBITDA | 0.07 | 0.07 | 0.09 | 0.09 | 0.09 | Upgrade |
EBIT | -0.63 | -0.26 | 0.38 | -0.78 | 0.6 | Upgrade |
EBIT Margin | -5.52% | -2.49% | 2.73% | -6.92% | 4.69% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.